6 results about "Motor symptoms" patented technology

The present disclosure relates to methods and compositions for treating Parkinson's disease, a neurodegenerative disorder characterized by loss of dopaminergic neurons. In particular, the present disclosure provides preparations of dopaminergic cells that have been demonstrated to have therapeutic effects on both motor and non-motor symptoms of the disease.

This invention proposes an early detection method for Parkinson's disease based on EfficientNetV2-S. Addressing the problems of traditional diagnosis relying on subjective assessment of motor symptoms by doctors, which is prone to misdiagnosis and missed diagnosis in the early stages, this method acquires handwritten images through spiral drawing and waveform handwriting tasks. It then utilizes EfficientNetV2-S to automatically learn subtle jitter features and motion control anomalies in the trajectory. Multi-scale feature fusion enhances the perception of minute local changes, and dual-task joint learning improves the comprehensive discrimination ability across different handwriting tasks. After automatic alignment, size normalization, and data augmentation, the data is input into the model, achieving high-precision, high-efficiency, non-invasive, and easily scalable early screening and assisted diagnosis.

The present disclosure provides a method of treating Dementia with Lewy Bodies (DLB) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula Compound I or a pharmaceutically acceptable salt thereof. The method improves cognition, activities of daily living, neuropsychiatric symptoms, and motor symptoms in the subject. The compound may be administered orally for about 6 months or longer, with a total daily dose of about 100 mg to about 300 mg. The method results in improvements in various assessment scales including Montreal Cognitive Assessment Scale (MOCA), Cognitive Drug Research Battery (CDR), Clinician Assessment of Fluctuation (CAF), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI), and Unified Parkinson's Disease Rating Scale (UPDRS).

Idiopathic Parkinson's disease (iPD) is a multi-system disorder, and the debilitating motor stage of iPD can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD) and gastrointestinal symptoms. Widespread immune dysregulation has been reported in clinically diagnosed iPD, but the existence of immune deficits during the prodromal stage has yet to be thoroughly investigated. Here, it was shown that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the immuno-metabolic response to stimulation of peripheral blood immune cells ex vivo. Peripheral blood monocytes from RBD patients displayed increased stimulation-dependent secretion of inflammatory cytokines, including TNF, IL-1β, and IL-8, which peaks in the prodromal stage and successively diminishes as PD progresses. Furthermore, T lymphocyte mitochondrial health was correlated with stimulation-evoked cytokine secretion across patients with RBD, early-stage iPD, and moderate-stage iPD. The results disclosed here have broad implications for mechanistic understanding of how peripheral inflammation may drive disease progression, and it reveals novel biomarkers to enable patient stratification and progression monitoring for clinical trials based on immune endophenotypes.

This invention relates to an odor combination for improving non-motor symptoms of Parkinson's disease. Its active ingredients consist of phenylethanol, eucalyptol, citronellol, and eugenol in a mass ratio of 0.5-2:0.5-2:0.5-2:0.5-2, with menthol microcapsules as the functional adjuvant. Each active ingredient is mixed with the menthol microcapsules in a mass ratio of 2-4:1, and the active ingredients are layered on a hydrogel material. The odor combination can be used alone or in conjunction with a breathing guide to form a multi-layered controlled-release olfactory training component. The odor combination and olfactory training component can generate a more progressive and hierarchical odor stimulation pattern that conforms to the laws of neural information processing, inducing stronger neural plasticity; it can also improve the experience and enjoyment of the training process, thereby increasing the long-term training compliance of Parkinson's disease patients; and the added adjuvant, without interfering with the main olfactory training, helps to regulate the patient's emotions and attention, thus producing a synergistic therapeutic effect.